Our experience and expertise will help accelerate your drug development program
With over 20 years of experience in drug development, we have the expertise to accelerate your biomarker and diagnostic program in any stage of development.
Understand protein expression patterns and localization at any stage of development
Accelerate your R&D and save precious clinical material with simultaneous detection of multiple targets
Understand complex cell interactions, unlock biological pathways, and identify clinically relevant biomarker signatures with high spatial resolution from a single tissue section.
Sensitive, high-throughput, and quantitative, gene expression analysis
Make accurate and informed decisions throughout drug and diagnostic development
Expert pathologist training to expedite clinical trials and accelerate post-approval studies and diagnostic adoption.
Get high quality results at speed and scale to accelerate global clinical trials using a single chain of custody that adheres to appropriate regulations and quality standards
“We have been working with Discovery Life Sciences in Kassel, previously Targos GmbH, for many years on clinical validation of tissue biomarkers. This partnership is based on strong scientific focus and an open and honest relationship which led to the approvals of many companion diagnostics assays for Agilent and our pharma partners. We always appreciate the consistent high-quality services and the mutual trust we've developed over the years across our various internal functions such as R&D, Marketing, CDx, and Clinical Trials. DLS has also established a fantastic Biomarker Academy training program that, in my opinion, has become a valuable cornerstone in the global pathology community.”
We worked with 3 histology vendors to develop IHC assay for novel tumor antigen using commercially available IHC antibodies. Only the DLS team was able to deliver robust and specific assay with staining characteristics that were suitable for our range-finding studies. Leveraging their in-house biorepository, DLS was able to deliver a data package with scoring intensities for this antigen for 178 patient samples across 13 cancer indications. This information has been extremely valuable in understanding the clinical opportunity that targeting this antigen would provide.
In the past five of years, we have entrusted Discovery Life Sciences with the development and validation of a FISH assay for a novel biomarker (MAF-Test) predicting relapse in breast cancer and the response to specific drugs in adjuvant setting. DLS's expertise in assay development and target validation helps create a reliable scoring scheme accelerating identification of patients eligible for further treatment. Furthermore, DLS's experience in molecular pathology and consultative service approach always exceeded our expectations
Expertise across different molecular pathology platforms in CLIA-certified, CAP-accredited, and GCLP-compliant laboratories.
Join the Poster Sessions Poster Session 1: Monday, February 24th (P08.03) Considerations for Large Cohort Exploratory Studies: Proof-of-Concept Using Stage-IV Oncology Plasma from 500 Donors Presented by: Danielle Gutierrez, Ph.D […]
Join us at TriCon 2025 at Booth #9 Discovery will also feature three scientific sessions led by Dr. Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens. Luncheon presentation […]
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2025 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
